ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last681 to 700 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With All-Cause Death68 of 6,589

58 of 6,610

0.2 points

-0.2 to 0.5

13,199NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Fatal Stroke18 of 6,589

17 of 6,610

0.0 points

-0.2 to 0.2

13,199NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Composite of Ischaemic Stroke, MI and CV Death423 of 6,589

475 of 6,610

-0.8 points

-1.6 to 0.1

13,199NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Ticagrelor 90 mg vs ASA 100 mg: Number of Participants by Severity of Stroke and Overall Disability1,107 of 6,589

1,194 of 6,610

-1.3 points

-2.6 to 0.0

13,199NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Stroke390 of 6,589

450 of 6,610

-0.9 points

-1.7 to -0.1

13,199NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Ticagrelor 90 mg vs ASA 100 mg: Net Clinical Outcome457 of 6,589

508 of 6,610

-0.7 points

-1.6 to 0.1

13,199NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Disabling Stroke277 of 6,589

307 of 6,610

-0.4 points

-1.1 to 0.3

13,199NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With MI25 of 6,589

21 of 6,610

0.1 points

-0.1 to 0.3

13,199NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Double Blind Phase: Ad26.COV2.S vs Double Blind Phase: Placebo: Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 Regardless of Serostatus With Onset at Least 14 Days After the Second Vaccination14 of 6,813

53 of 6,370

-0.6 points

-0.9 to -0.4

13,183NCT04614948

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event82 of 6,549

37 of 6,581

0.7 points

0.4 to 1.0

13,130NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With PLATO Major Bleeding Event31 of 6,549

38 of 6,581

-0.1 points

-0.4 to 0.1

13,130NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

ASA 100mg vs Ticagrelor 90mg: serious adverse events533 of 6,581

532 of 6,549

-0.0 points

-1.0 to 0.9

13,130NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Epanova vs Placebo: deaths from any cause373 of 6,539

333 of 6,539

0.6 points

-0.2 to 1.4

13,078NCT02104817

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Epanova vs Placebo: serious adverse events2,259 of 6,532

2,195 of 6,535

1.0 points

-0.6 to 2.6

13,067NCT02104817

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Darapladib 160 mg vs Placebo: Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal MI or Non-fatal Stroke) During the Time Period for Follow-up of CV Events824 of 6,504

838 of 6,522

-0.2 points

-1.3 to 1.0

13,026NCT01000727

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Darapladib 160 mg vs Placebo: Number of Participants With Urgent Coronary Revascularization for Myocardial Ischemia During the Time Period for Follow-up of Cardiovascular Events237 of 6,504

218 of 6,522

0.3 points

-0.3 to 0.9

13,026NCT01000727

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Darapladib 160 mg vs Placebo: Number of Participants With First Occurrence of Any Component of the Composite of All-cause Mortality, Non-fatal MI, or Nonfatal Stroke During the Time Period for Follow-up of Cardiovascular Events914 of 6,504

928 of 6,522

-0.2 points

-1.4 to 1.0

13,026NCT01000727

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Darapladib 160 mg vs Placebo: Number of Participants With First Occurrence of Any Event in the Composite of Total Coronary Events (CHD Death, Non-fatal MI, Hospitalization for Unstable Angina, or Any Coronary Revascularization Procedure) During the Time Period for FU of CV Events1,290 of 6,504

1,352 of 6,522

-0.9 points

-2.3 to 0.5

13,026NCT01000727

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Darapladib 160 mg vs Placebo: Number of Participants With First Occurrence of MI (Fatal/Nonfatal) During the Time Period for Follow-up of Cardiovascular Events547 of 6,504

564 of 6,522

-0.2 points

-1.2 to 0.7

13,026NCT01000727

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Darapladib 160 mg vs Placebo: Number of Participants With CHD Death During the Time Period for Follow-up of Cardiovascular Events211 of 6,504

241 of 6,522

-0.5 points

-1.1 to 0.2

13,026NCT01000727

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=35

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01994720-9efcc190",
        "title": "Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With All-Cause Death",
        "summary": "68 of 6589 against 58 of 6610; risk difference 0.2 points, 95% interval -0.2 to 0.5; NCT01994720, [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]",
        "record": "/library/comparisons/NCT01994720-9efcc190",
        "nct_id": "NCT01994720",
        "kind": "outcome",
        "participants": 13199,
        "risk_difference": {
          "value": 0.0015456467238181074,
          "lower": -0.0018039603592624421,
          "upper": 0.004927563031373301
        },
        "group_1": "68 of 6,589",
        "group_2": "58 of 6,610",
        "difference": "0.2 points",
        "interval": "-0.2 to 0.5",
        "trial_title": "[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]"
      },
      {
        "id": "NCT01994720-ad276aef",
        "title": "Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Fatal Stroke",
        "summary": "18 of 6589 against 17 of 6610; risk difference 0.0 points, 95% interval -0.2 to 0.2; NCT01994720, [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]",
        "record": "/library/comparisons/NCT01994720-ad276aef",
        "nct_id": "NCT01994720",
        "kind": "outcome",
        "participants": 13199,
        "risk_difference": {
          "value": 0.0001599649532790749,
          "lower": -0.0016806463634924205,
          "upper": 0.0020137615073471922
        },
        "group_1": "18 of 6,589",
        "group_2": "17 of 6,610",
        "difference": "0.0 points",
        "interval": "-0.2 to 0.2",
        "trial_title": "[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=36",
  "request_id": "0_dntqKUT5PHGp9r"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?